ArQule Inc. has enrolled its first patient in a Phase 1 clinical trial aimed at testing ARQ 736, its small molecule inhibitor of the RAF kinases, ArQule officials announced today in a press release.

The trial is expected to evaluate the safety and tolerability of ARQ 736. an inhibitor of the pan-RAF enzyme that has also showed promise as an inhibitor of other mutant kinases. This trial will test ARQ 736 in cancer patients with solid tumors that have the mutant BRAF kinase.